First Bank & Trust Takes Position in GSK PLC Sponsored ADR $GSK

Key Points

• First Bank & Trust has acquired a new position in GSK PLC Sponsored ADR, purchasing 31,667 shares valued at approximately $1.22 million in the second quarter of 2023.
• GSK reported a Q2 earnings per share (EPS) of $1.23, surpassing estimates, and had revenue of $10.64 billion, significantly exceeding expectations.
• The company announced a $0.4206 quarterly dividend with a yield of 4.2%, but also cut its dividend payout ratio to 77.78%.

First Bank & Trust acquired a new position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 31,667 shares of the pharmaceutical company's stock, valued at approximately $1,216,000.

Several other large investors have also recently made changes to their positions in GSK. NewEdge Advisors LLC raised its stake in GSK by 8.6% during the 1st quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company's stock valued at $3,512,000 after buying an additional 7,148 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of GSK by 201.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company's stock valued at $154,244,000 after acquiring an additional 2,663,270 shares during the period. Everstar Asset Management LLC boosted its holdings in GSK by 230.3% in the 1st quarter. Everstar Asset Management LLC now owns 26,300 shares of the pharmaceutical company's stock worth $1,019,000 after buying an additional 18,337 shares during the period. Bard Financial Services Inc. boosted its holdings in GSK by 10.2% in the 2nd quarter. Bard Financial Services Inc. now owns 134,745 shares of the pharmaceutical company's stock worth $5,174,000 after buying an additional 12,500 shares during the period. Finally, Fred Alger Management LLC boosted its holdings in GSK by 16.7% in the 1st quarter. Fred Alger Management LLC now owns 51,693 shares of the pharmaceutical company's stock worth $2,020,000 after buying an additional 7,390 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on GSK shares. Berenberg Bank restated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 5th. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, GSK currently has an average rating of "Reduce" and an average target price of $37.38.

GSK Price Performance

GSK stock traded up $0.33 during trading on Friday, hitting $40.63. The company had a trading volume of 3,691,363 shares, compared to its average volume of 3,611,408. The firm has a market capitalization of $82.75 billion, a price-to-earnings ratio of 18.81, a P/E/G ratio of 2.01 and a beta of 0.53. The business has a 50 day moving average of $38.90 and a 200 day moving average of $38.55. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $42.63. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. GSK's dividend payout ratio is currently 77.78%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.